Published in Arthritis Res Ther on March 18, 2011
Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J Clin Invest (2015) 1.51
Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum (2013) 1.27
The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) (2013) 1.19
The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) (2013) 1.10
Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev (2014) 0.99
Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol (2015) 0.93
Latest advances in connective tissue disorders. Ther Adv Musculoskelet Dis (2013) 0.85
The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies. Arthritis Res Ther (2014) 0.80
Fatal cardiac involvement complicating antisynthetase syndrome. BMJ Case Rep (2014) 0.79
Autoantibodies to transcription intermediary factor TIF1β associated with dermatomyositis. Arthritis Res Ther (2012) 0.78
Lupus pathobiology based on genomics. Immunogenetics (2016) 0.78
T cells in myositis. Arthritis Res Ther (2012) 0.78
Mechanisms of Autoantibody-Induced Pathology. Front Immunol (2017) 0.76
Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. Arthritis Res Ther (2016) 0.75
Pure White Cell Aplasia and Necrotizing Myositis. Case Rep Hematol (2016) 0.75
Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research. Curr Opin Rheumatol (2014) 0.75
Functional redundancy of MyD88-dependent signaling pathways in a murine model of histidyl-transfer RNA synthetase-induced myositis. J Immunol (2013) 0.75
[Dermatomyositis-specific antibodies]. Z Rheumatol (2015) 0.75
[New aspects on the pathogenesis of myositis]. Z Rheumatol (2013) 0.75
Polymyositis and dermatomyositis (first of two parts). N Engl J Med (1975) 18.52
Polymyositis and dermatomyositis (second of two parts). N Engl J Med (1975) 7.26
FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell (2009) 4.11
A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum (2010) 3.17
Classification criteria for polymyositis and dermatomyositis. J Rheumatol (1995) 3.08
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med (2005) 2.82
Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med (1999) 2.81
Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis (2001) 2.69
RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum (2009) 2.37
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum (2005) 2.11
A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum (2006) 1.93
Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry (2002) 1.84
Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) (2009) 1.79
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med (2002) 1.78
Antibody to signal recognition particle in polymyositis. Arthritis Rheum (1990) 1.74
The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis (2007) 1.66
The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum (1985) 1.62
The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) (2009) 1.62
Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis (2006) 1.54
Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) (2006) 1.53
Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) (2010) 1.49
Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum (2009) 1.37
Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor. Nucleic Acids Res (2001) 1.34
Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum (2009) 1.31
A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum (2007) 1.31
Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum (2007) 1.28
Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity (2006) 1.27
Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A (1986) 1.25
In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther (2006) 1.23
The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny. Development (2007) 1.21
Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum (2007) 1.17
Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum (2006) 1.14
Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol (2009) 1.13
Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) (2007) 1.10
HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) (2007) 1.08
Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum (2007) 1.04
Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) (2010) 1.04
Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum (2009) 1.03
Clinical and serological aspects of patients with anti-Jo-1 antibodies--an evolving spectrum of disease manifestations. Clin Rheumatol (2000) 1.02
UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem (2008) 1.02
Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine (2010) 1.00
Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol (2010) 1.00
The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains. J Biol Chem (2002) 0.99
Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum (2007) 0.99
Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol (2007) 0.98
Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol (2009) 0.97
A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum (1994) 0.94
Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol (2008) 0.93
Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology (Oxford) (2007) 0.91
Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol (1996) 0.89
Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis (2008) 0.89
Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. Arthritis Rheum (2009) 0.84
Landscape of transcription in human cells. Nature (2012) 20.18
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) (2012) 3.56
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum (2006) 3.45
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet (2010) 2.56
Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) (2009) 1.79
Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol (2006) 1.13
Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol (2007) 1.12
Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum (2007) 1.04
Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res Ther (2013) 1.04
Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol (2008) 0.98
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology (Oxford) (2013) 0.95
Work disability in psoriatic arthritis: a systematic review. Rheumatology (Oxford) (2011) 0.93
Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum". Autoimmun Rev (2013) 0.93
Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. Arthritis Rheum (2013) 0.91
Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locus. Arthritis Rheum (2011) 0.90
Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther (2014) 0.89
The evolving spectrum of polymyositis and dermatomyositis--moving towards clinicoserological syndromes: a critical review. Clin Rev Allergy Immunol (2014) 0.88
The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol (2013) 0.88
Pathogenic mechanisms of disease in myositis: autoantigens as clues. Curr Opin Rheumatol (2009) 0.87
Antinuclear antibodies and clinical associations in a british cohort with limited cutaneous systemic sclerosis. J Rheumatol (2011) 0.87
Drug use and toxicity in psoriatic disease: focus on methotrexate. J Rheumatol (2008) 0.84
Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol (2010) 0.84
Genetic association study of NF-κB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy. Rheumatology (Oxford) (2011) 0.84
Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis. Rheumatology (Oxford) (2012) 0.84
HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. Rheumatology (Oxford) (2009) 0.82
Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11. J Rheumatol (2014) 0.81
Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group. J Rheumatol (2011) 0.81
Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies. Curr Rheumatol Rep (2014) 0.80
The impact of group education on participants' management of their disease in lupus and scleroderma. Musculoskeletal Care (2004) 0.80
Use of infrared thermography as an endpoint in therapeutic trials of Raynaud's phenomenon and systemic sclerosis. Clin Exp Rheumatol (2012) 0.78
Mortality and causes of death in psoriatic arthritis. J Rheumatol Suppl (2012) 0.76
Evaluating factors influencing screening for pulmonary hypertension in systemic sclerosis: does disparity between available guidelines influence clinical practice? Clin Rheumatol (2011) 0.76
Missing laboratory test data in electronic general practice records: analysis of rheumatoid factor recording in the clinical practice research datalink. Pharmacoepidemiol Drug Saf (2015) 0.75
Vacuum-assisted closure therapy: a novel treatment for wound healing in systemic sclerosis. Rheumatology (Oxford) (2010) 0.75
Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients. J Rheumatol (2017) 0.75